M&A Deal Summary

GSK Acquires Tesaro

On December 3, 2018, GSK acquired life science company Tesaro for 5.1B USD

Acquisition Highlights
  • This is GSK’s 21st transaction in the Life Science sector.
  • This is GSK’s 2nd largest (disclosed) transaction.
  • This is GSK’s 14th transaction in the United States.
  • This is GSK’s 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2018-12-03
Target Tesaro
Sector Life Science
Buyer(s) GSK
Deal Type Add-on Acquisition
Deal Value 5.1B USD
Advisor(s) Centerview Partners
Citi (Financial)
Ropes & Gray
Hogan Lovells (Legal)

Target

Tesaro

Waltham, Massachusetts, United States
Tesaro, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of patients with cancer. Tesaro develops and will commercialize safer and more effective supportive care agents and therapeutics. Tesaro, Inc. was founded in 2010 and is based in Waltham, Massachusetts.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

GSK

Brentford, United Kingdom
Category Company
Founded 1715
Sector Life Science
Employees70,212
Revenue 30.3B GBP (2023)
DESCRIPTION
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.

GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.

DEAL STATS #
Overall 25 of 32
Sector (Life Science) 21 of 26
Type (Add-on Acquisition) 19 of 24
State (Massachusetts) 2 of 3
Country (United States) 14 of 19
Year (2018) 1 of 1
Size (of disclosed) 2 of 28
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-30 GlaxoSmithKline - Consumer Healthcare Portfolio

Brentford, United Kingdom

GlaxoSmithKline plc - Consumer Healthcare Portfolio has long been regarded as high quality, safe and effective, maintaining a quality image and loyal base of consumers. OTC medications allow practitioners and their patients the ability to access therapeutic products while reducing the burden of prescription drug costs on the healthcare system. The products expand Crown Laboratories’ consumer portfolio by adding #1 in category brands that treat multiple conditions. The acquired portfolio includes PanOxyl®: #1 Dermatologist recommended daily acne wash Sarna®: #1 Dermatology recommended anti-itch lotion Zeasorb®: #1 Dermatologist recommended anti-fungal and prevention product Desenex®: Anti-fungal powder for athlete’s foot Mineral Ice®: Leading pain-relieving gel.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-01 GlaxoSmithKline - Keri

Brentford, United Kingdom

GlaxoSmithKline plc - Keri is a major skin care brand with a rich heritage. Keri has a long and successful history in the market, supported by dermatologists and healthcare practitioners across the world.

Sell -
Mergr

Product

Company

Legal